Mr Macron was due to unveil the multi-billion euro fund aimed at restarting the recovery this month. The coronavirus recovery package will now be r
Mr Macron was due to unveil the multi-billion euro fund aimed at restarting the recovery this month. The coronavirus recovery package will now be released in the first week of September. Businesses in the country had eagerly awaited to hear the Government’s plan but will now wait until next month as Mr Macron focuses on reopening schools instead.
Government spokesman, Gabriel Attal said: “The recovery plan is ready, the timetable for its implementation still stands.”
Schools in France are due to open on September 1 despite fears of a second wave of the virus rising.
Currently, the country has recorded 234,400 cases with a further 30,503 deaths at the time of writing.
Due to the fears of a second wave of the virus, France was placed on the UK’s quarantine watch list last Friday.
According to the European Centre for Disease and Prevention Control, France now has 54.4 cases per 100,000 people.
That is one of the highest 14-day cumulative numbers across the continent, with only Spain (152.7), Romania (88), Luxembourg (96.3) and Malta (119.5) having higher rates.
Combined with high case total, the French economy also suffered one of its worst contractions in history earlier this month.
According to official statistics, France experienced a 13.8 percent contraction in the second quarter of this year.
JUST IN: EU insight: Charles Michel’s ‘NUCLEAR plan’ in case of Macron’s exit
“And to ensure that we will have the capacity to produce them and deliver them to our populations when they are available.”
Amid the race for a vaccine, the European Commission has announced a deal for 225 million doses of a possible drug.
The EU agreed the deal with German company, CureVac on Thursday.
Likewise, Russia claimed to have produced the first licensed vaccine which will be sent to 40,000 people for continued trials next week.
The UK has also signed a deal for up to 90 million potential doses from Belgium’s Janssen and US biotech company, Novavax.